717 Shares in Axon Enterprise, Inc $AXON Acquired by Union Bancaire Privee UBP SA

Key Points

• Union Bancaire Privee UBP SA acquired 717 shares of Axon Enterprise, Inc, amounting to approximately $594,000, reflecting continued interest from institutional investors, with 79.08% of the stock now held by such funds.
• Recent insider activity included President Joshua Isner selling 15,919 shares valued at nearly $11.88 million, which decreased his position by 6.26%.
• Analyst ratings remain mixed, with Zacks downgrading Axon from a "strong-buy" to a "hold," while Bank of America increased its price target, maintaining a "buy" rating, indicating a diverse outlook among financial experts on the stock's potential.

Union Bancaire Privee UBP SA bought a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 717 shares of the biotechnology company's stock, valued at approximately $594,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TCI Wealth Advisors Inc. purchased a new stake in Axon Enterprise in the 2nd quarter worth approximately $214,000. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Axon Enterprise in the 1st quarter worth approximately $1,110,000. Quotient Wealth Partners LLC bought a new position in Axon Enterprise in the 1st quarter worth approximately $438,000. CX Institutional bought a new position in Axon Enterprise in the 1st quarter worth approximately $115,000. Finally, GAMMA Investing LLC boosted its stake in Axon Enterprise by 11.8% in the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock worth $765,000 after purchasing an additional 154 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 15,919 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the sale, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeri Williams sold 100 shares of the stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director owned 1,416 shares in the company, valued at $1,065,596.64. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,932 shares of company stock worth $37,978,216 in the last ninety days. Corporate insiders own 5.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AXON shares. Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 2nd. Bank of America upped their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Needham & Company LLC restated a "buy" rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. UBS Group restated a "neutral" rating and issued a $840.00 price target (up from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Raymond James Financial restated an "outperform" rating and issued a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $841.64.

Axon Enterprise Stock Up 0.2%

NASDAQ AXON opened at $717.64 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market capitalization of $56.34 billion, a P/E ratio of 177.20, a P/E/G ratio of 27.80 and a beta of 1.40. Axon Enterprise, Inc has a one year low of $395.37 and a one year high of $885.91. The stock has a 50 day moving average price of $757.83 and a 200-day moving average price of $704.96.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company's quarterly revenue was up 32.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.